PR negative

About

Biomarker type: Protein expression

Marker: Progesterone receptor (PR)

Unit: status

Equality: =

Value: Negative

Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (1) HSE (4) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab
EMA (1) FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab
EMA (2) FDA (1) HSE (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Nab-paclitaxel, Pembrolizumab
EMA (1) HSE (1) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel
EMA (1) ER positive, HER2-positive, PR negative Invasive Breast Carcinoma Lapatinib, Trastuzumab
EMA (1) ER positive, ERBB2 amplification, PR negative Invasive Breast Carcinoma Lapatinib, Trastuzumab